Discovery Matters artwork

75. The state of the industry

Discovery Matters

English - June 22, 2023 14:23 - 33 minutes - 30.5 MB - ★★★★★ - 19 ratings
Life Sciences Science Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: 74. Patient-derived organoids
Next Episode: 76. Liquid biopsy

Why do China and US have different government regulations? Why can’t we do business above the fray?


These are just some of the struggles biopharma executives report impacting their business. Our guests are of the same view – the industry needs fixing.


Yingke He, CEO and Co-Founder of Forecyte Bio, explains how China's industrialized experience is limited and in its early stages compared to the US.


Listen to this episode to understand the industry tensions and areas showing promise.




Transcript




Show notes


The Biopharma Resilience Index - Biopharma Resilience | Cytiva (cytivalifesciences.com)


Pessimists Archive - Pessimists Archive


Caesarean babies and their mother’s microbiome - 'Vaginal seeding' boosts the development of babies born by C-section | New Scientist


Keywords: talent, industry, manufacturing, collaboration, pandemic, therapies, challenges, government, regulators, biopharma resilience index, policies, solutions, companies, China, genomic medicine, cell and gene therapy.